Drug intelligence / Profile preview

HRS2300 + SHR-1316

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

HRS2300 + SHR-1316 is an experimental combination therapy studied in patients with advanced malignant tumors. HRS2300 is a chemical compound classified as an antineoplastic agent with an as-yet undefined mechanism of action. SHR-1316 is a monoclonal antibody targeting programmed death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. The combination was evaluated in early-phase clinical trials for its safety and tolerability, primarily in solid tumors and advanced cancers, with the expectation that HRS2300’s antineoplastic activity may synergize with the immunomodulatory effects of SHR-1316. Both components are being developed by Jiangsu Hengrui Pharmaceuticals.

Other names: HRS-2300 + SHR-1316

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on HRS2300 + SHR-1316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS2300 + SHR-1316.

Explore the full profile